News
Centauri Therapeutics receives an additional $5.1M from CARB-X to progress ABX-01 lead compound to first in human clinical trials CARB-X provides an additional $5.1M to complete the non-clinical ...
Materials innovation company, Xampla, announces a major commercial advance as Bunzl UK & Ireland add Huhtamaki’s ‘Taste’ hot ...
The progression to a Phase IIb clinical study follows encouraging results from Exonate’s Phase Ib/IIa study in March 2024 1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback